Litwin MS, Hays RD, Fink A, et al. The UCLA Prostate Cancer Index: Development, reliability, and validity of a health-related quality of life measure. Med Care 1998;36:1002-12.
Wei J, Dunn RL. Litwin MS, Sandler HM, Sanda MS. Development and Validation of the Expanded Prostate Cancer Index Composite (EPIC) for Comprehensive Assessment of Health-Related Quality of Life in Men with Prostate Cancer. Urology 2000;56:899-905.
EuroQol Group. A new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions: Health Utilities Index. PharmacoEconomics 1995;7:503-20.
Krahn M, Ritvo P, Irvine J, et al. Construction of the Patient-Oriented Prostate Utility Scale (PORPUS): a multiattribute health state classification system for prostate cancer. J Clin Epidemiol 2000;53:920-30.
Froberg DG, Kane RL. Methodology for measuring health-state preferences-II: scaling methods. J Clin Epidemiol 1989;42:459-71.
Bremner KE, Tomlinson G, Krahn MD. Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients. Qual Life Res 2007;16:1665-75.
Torrance G, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multi-attribute preference functions for a comprehensive health state classification system: Health Utilities Index Mark 2. Med Care 1996;34:702-22.
Ritvo P, Irvine J, Naglie G, et al. Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer. J Clin Epidemiol 2005;58:466-74.
Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qual Life Res 2007;16:509-22.
Krahn MD, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: Implications for clinical policy. Med Care 2003;41:153-64.
Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 2006;176:2443-7.
Krahn MD, Bremner KE, Tomlinson G, Naglie G. Utility and health-related quality of life in prostate cancer patients twelve months following radical prostatectomy or radiation therapy. Prostate Cancer and Prostatic Diseases 2009;12:4:361-368.
Matthew AG, Currie KL, Irvine J, et al. Serial personal digital assistant data capture of health-related quality of life: a randomized controlled trial in a prostate cancer clinic. Health & Quality of Life Outcomes 2007;5:38.
Krahn M.D. BK, Tomlinson G, Alibhai SMH, Laporte A, Naglie G. Effect of age on preferences for health outcomes in prostate cancer. Presented as a poster at the American Society of Clinical Oncology, Prostate Cancer Symposium, February 22-24, 2007, Orlando, Florida
Bremner KE, Carcone SM, Kowgier ME, et al. Clinical and demographic predictors of quality of life in prostate cancer survivors. Value in Health 2008;11:A73.
Kilbridge KL, Fraser G, Krahn M, et al. Lack of comprehension of common prostate cancer terms in an underserved population. J Clin Oncol 2009;27:2015-21.
Waldmann A, Rohde V, Bremner K, Krahn M, Kuechler T, Katalinic A. Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P). BMC Cancer 2009;9:295.
Development and validation of a utility weighting function for the PORPUS- Patient Oriented Prostate Utility Scale Tomlinson G, Bremner KE, Ritvo P, Naglie G, Krahn MD. Medical Decision Making, published online 8 June 2011 DOI: 10.1177/0272989X11407203